3SBio completes take-private deal

The Chinese biotech firm is quitting Nasdaq for a possible listing in Hong Kong.

3SBio completes take-private deal

Citic Private Equity and the chief executive of Nasdaq-listed 3SBio, a Chinese biotech firm, have completed a take-private deal that values the company at $370 million and paves the way for an offering in Hong Kong.

Under the terms of the merger agreement, holders of the company's ordinary shares and American depositary shares each representing seven shares will receive $2.39 a share or $16.70 per ADS.

That gives shareholders a 44%...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES